Baseline PSA nadir >= . ng/ml (post-operative value is never undetectable) obtained prior to step  registration
Previously untreated localized adenocarcinoma of the prostate with the following clinical findings:\r\n* Clinical stage by digital rectal exam of either Tc or Ta/b (limited to one side of the gland); (American Joint Committee on Cancer [AJCC], version ) or cTa-c or a or b, stage group IIA or IIB (AJCC, version ); both versions  and  staging should be recorded\r\n* Patients in active surveillance who elect to be treated are eligible if they meet protocol requirements\r\n* Stages Ta-Tb are eligible if patient underwent transurethral prostatic resection (TURP) previously Gleason score must be Gleason (+) with a PSA <  ng/mL, or Gleason (+) with a PSA >  ng/mL and <  ng/mL; (AJCC, version ) or group grade  or , stage Group IIA or IIB (AJCC version )\r\n** If patient is receiving a -alpha reductase inhibitor at the time of enrollment the baseline PSA value will be assumed to be double the initial value and the medication should be discontinued but does not need to have a washout period to participate, to remain eligible a PSA drawn while still on the medicine must be:\r\n*** <  ng/mL to remain eligible if Gleason (+) \r\n**** Stratification level  if PSA <  ng/mL and level  if less than  ng/mL\r\n*** >  ng/mL and less than  ng/mL for Gleason (+) \r\n**** Stratification level \r\n* Percent of submitted positive core biopsies must be < % of all sextants\r\n** NOTE: all cores from a targeted lesion will be counted as an N of  core for calculating percent positive cores in total\r\n* The prostate volume must be <  cc as reported at time of biopsy or by separate measure with ultrasound or other imaging modalities including magnetic resonance imaging (MRI) or computed tomography (CT) scan
Recurrent prostate cancer following primary therapy as defined by:\r\n* Post-radical prostatectomy: Any PSA >= . ng/ml\r\n* Post-primary radiotherapy: PSA >=  ng/ml above a post-radiotherapy nadir\r\n* Post-primary androgen-deprivation therapy: A confirmed rise of PSA >=  ng/ml above a post-therapy nadir
For patients with castrate levels of circulating androgen levels (testosterone <  ng/dl):\r\n* PSA levels must be >= . ng/ml (if history of radical prostatectomy) or >=  ng/ml (if history of non-surgical primary treatment) and found to be increasing on at least two occasions >=  week apart\r\n* At least  weeks must have elapsed since any changes to hormonal therapy, including at least  weeks since flutamide and at least  weeks since bicalutamide, nilutamide, or enzalutamide
PSA ?  ng/ml
Evidence of disease recurrence or progression as evidenced by a PSA > .; this requires  consecutive rises in PSA, at least  week apart, over the post-prostatectomy nadir or one PSA value above . ng/mL if the patient failed to achieve a post-prostatectomy nadir of < . ng/mL
PSA > . ng/mL
Absolute PSA >  ng/mL AND/OR
Very fast PSA doubling time of less than  weeks, if the absolute PSA is >  ng/mL or an absolute PSA value of greater than or equal to  ng/ml
Screening PSA > . ng/mL
Screening PSA must be >= . ng/mL
PSA <  ng/ml or PSA density < . ng/ml in patients with a PSA >  ng/ml
PSA must be <  ng/mL at study entry
Serum PSA >= . ng/mL
For patients following radical prostatectomy:  absolute PSA values > . ng/ml
PSA >=  ng/mL
Serum PSA =< . ng/ml
PSA values <  ng/ml within  days prior to enrollment. Obtained at least  weeks after surgery
Biochemical progression defined as follows:\r\n* For patients following definitive radiation therapy: a rise in PSA of >=  ng/mL above the nadir (per Radiation Therapy Oncology Group [RTOG]- American Society for Radiation Oncology [ASTRO] consensus criteria)\r\n* For patients following radical prostatectomy: rising PSA after surgical procedure (patients must have a PSA >= . ng/mL)
PSA =<  ng/mL
Serum PSA ? ng/mL.
Evidence of disease recurrence or progression as evidenced by a PSA > . ng/ml; this requires  consecutive rises in PSA, at least  week apart, over the post-prostatectomy nadir or one PSA value above . ng/mL if the patient failed to achieve a post-prostatectomy nadir of < . ng/mL
PSA ? . ng/mL
PSA >=  ng/ml
PSA >=  ng/dL
Has a serum PSA concentration at the Screening visit of > . ng/mL (. ?g/L), or, when applicable, post radical prostatectomy of > . ng/mL (. ?g/L) or post radiotherapy, cryotherapy, or high frequency ultrasound > . ng/mL (. ?g/L) above the post interventional nadir;
Creatinine =< . ng/mL for females; =< . ng/mL for males; patients with creatinine =< . ng/mL may still be eligible if in the opinion of the investigator, the benefits of treatment outweigh the risks
Absolute PSA >= ng/ml; prior undetectable PSA post-prostatectomy is not required
PSA >  ng/mL at baseline or prior to initiation of hormonal therapy
Screening PSA must be >= . ng/mL
Baseline serum ferritin level >=  ng/mL
Serum ferritin <  ng/mL
Prostate specific antigen (PSA) =<  ng/ml, obtained within  months
Patient has a PSA of greater than  ng/ml obtained no greater than  months prior to randomization
Serum PSA < ng/ml
PSA >  ng/mL in screening
Maximum PSA =<  ng/ml (not within  days after biopsy)
PSA >  ng/mL
PSA <  ng/mL
PSA >=  ng/mL
For patients with metastatic prostate cancer, PSA >=  ng/mL, except for patients who have recently started androgen deprivation therapy with PSA <  ng/mL
Prostate specific antigen (PSA) =<  ng/mL within  days prior to registration; PSA should not be obtained within  days after prostate biopsy
Serum PSA >  ng/dL
Prostate specific antigen (PSA) >= . ng/ml that is confirmed with a second PSA measurement
PSA >= . ng/mL
Very low risk category (Tc, GS ?, PSA < ng/mL, fewer than  prostate biopsy cores positive, ?% cancer in any core, PSA density <. ng/mL/g)
PSA of greater than ng/ml
Prostate specific antigen (PSA) =<  ng/dL
Prostate specific antigen (PSA) of less than  ng/ml
PSA >  ng/ml
CEA plasma levels >  ng/mL.
Castration resistant prostate cancer as defined by serum testosterone <  ng/ml and PSA level of at least  ng/ml that has risen on at least  successive occasions at least  week apart
CEA plasma levels >  ng/mL
Prostate cancer with a current PSA level < . ng/mL.
Serum ferritin <  ng/mL.
Normal serum CEA levels (<  ng/ml) at the time of registration
Serum prostate specific antigen (PSA) level <  ng/ml
Serum PSA level >  ng/ml
Prostate-specific antigen (PSA) <  ng/ml (this will be the PSA level prompting the initial prostate biopsy)
Serum PSA >= . ng/ml at study enrollment
Patients must have a PSA >=  ng/mL obtained within  days prior to registration
Serum PSA < ng/mL undergoing active surveillance may be enrolled with agreement of the sponsor.
Screening PSA by the central laboratory ?  ng/mL for patients who had radical prostatectomy (with or without radiotherapy) as primary treatment for prostate cancer and at least  ng/mL above the nadir for patients who had radiotherapy only as primary treatment for prostate cancer;
PSA ?  ng/ml
PSA >  ng/ml
Prostate-specific antigen doubling time of ?  months and PSA > ng/ml.
PSA and the screening PSA assessed by the central laboratory (central PSA) should be ?  g/L ( ng/mL:
Specific eligibility criteria for Part  CRPC expansion cohort: Prostate-Specific Antigen (PSA) levels >=. ng/mL. Note: If PSA level has been obtained within  days of Screening, this test does not need to be repeated and the result previously obtained may be used for the Screening value.
PSA progression defined as % increase over baseline value with an increase in the absolute value of at least  ng/mL that is confirmed by another PSA level with a minimum of a  week interval and a minimum PSA of  ng/mL.
PSA progression defined as % increase over a baseline value of >  ng/ml with an increase in the absolute value of at least  ng/mL that is confirmed by another PSA level with a minimum of a -week interval. Baseline is defined as the PSA nadir level since commencing most recent prior therapy
A post-prostatectomy PSA nadir >= . ng/mL AND Gleason >= 
pT with a negative surgical margin and PSA < . ng/mL
Serum prostate-specific antigen (PSA) ? ng/mL.
PSA ?  ng/mL;
PSA >  ng/mL
PSA progression defined as % increase over baseline value with an increase in the absolute value of at least  ng/mL that is confirmed by another PSA level with a minimum of a  week interval with a minimum PSA of  ng/ml.
Patients with a prostate serum antigen (PSA), equal to, or more than,  ng/mL.
Prostate cancer with a current PSA level < . ng/mL.
Patient with PSA less than or equal to  ng/mL
PSA <  ng/mL =<  days prior to registration
Biochemical progression after definitive radiation or surgery defined as follows:\r\n* For patients following definitive radiation therapy: a rise in PSA of >=  ng/mL above the nadir (per Radiation Therapy Oncology Group [RTOG]-American Society for Radiation Oncology [ASTRO] consensus criteria)\r\n* For patients following radical prostatectomy: rising PSA after surgical procedure; (patients must have a PSA >= . ng/ml)
PSA =<  ng/mL
Patients with prior history of prostate cancer that is not under active systemic treatment (except hormonal therapy), but with undetectable PSA (<. ng/mL).
The screening PSA (PSA) must be ?  ?g/L (?  ng/mL).
Patients must have a minimum serum PSA level of > ng/ml that is rising based on the Prostate Cancer Working Group  criteria.
Prostate-specific antigen (PSA) <  ng/dl
PSA value within  weeks of starting therapy less than  ng/mL for hormone-nave patients (defined as hormone-nave patients and patients who received hormone therapy in the past who currently have total testosterone greater than  ng/dL) or less than  ng/mL for hormone-independent patients.
An elevated PSA level of >  ng/mL for patients progressing by PSA criteria is required (last confirmatory sample must be >  ng/mL)
Serum PSA ? ng/mL (?g/L)
Serum PSA (Prostate specific antigen) progression defined as  subsequent increases in PSA over a previous reference value (a minimum of  ng/mL [?g/L]) OR
Patients must have an absolute PSA level between > . and < . ng/mL at the time of study entry
PSA >= . ng/mL
Biochemical progression defined as follows:\r\n* For patients following definitive radiation therapy: a rise in PSA of >=  ng/mL above the nadir (per Radiation Therapy Oncology Group [RTOG]-American Society for Radiation Oncology [ASTRO] consensus criteria)\r\n* For patients following radical prostatectomy: rising PSA after surgical procedure (patients must have a PSA >=  ng/ml)
PSA =<  ng/mL
Patients must have a PSA >=  ng/mL at the time of diagnosis of prostate cancer or later
PSA >  ng/mL
Prostate specific antigen (PSA) >  ng/ml, unless anaplastic features are present
PSA >  ng/mL (at the time of enrollment or prior to initiation of docetaxel)
Serum prostate specific antigen (PSA) <  ng/mL            \r\n* NOTE: baseline PSA for determination of eligibility must be measured after discontinuation of any -alpha reductase inhibitors
The most recent of the PSA values must be >= . ng/ml; this measurement must be obtained within  month prior to enrollment
serum prostate specific antigen (PSA) ?. ng/mL and ? ng/mL;
Pre-registration serum PSA level =<  ng/mL
All patients must have a PSA >=  ng/mL
 ng/mL < serum ferritin < , ng/mL (Values within % difference above  ng/ml or % difference below  ng/ml may be accepted at the investigator's discretion.
Prostate cancer with a current PSA level < . ng/mL.
After radical prostatectomy, two PSA measurements of ? . ng/mL at least one week apart;
After cryosurgery, two PSA measurements of ? . ng/mL at least one week apart;
A PSA value of at least  ng/mL is required at study entry.
Biochemical disease progression after radical prostatectomy and/or radiation therapy (external-beam radiation therapy and/or brachytherapy), and no radiographic evidence of metastases\r\n* Men with history of radical prostatectomy are required to have baseline PSA > . ng/mL (prior treatment with neoadjuvant, adjuvant, or salvage radiation therapy is allowed, again, with screening PSA greater than or equal to . ng/mL required for eligibility)\r\n* Men treated with primary radiation therapy are required to have baseline PSA >= . ng/mL above their post radiation nadir for men who were treated with primary radiation therapy (external beam and/or brachytherapy); men who had primary radiation therapy followed by salvage prostatectomy are eligible if screening PSA is greater than or equal to . ng/mL\r\n* Men with previous neoadjuvant adjuvant hormone therapy are eligible if testosterone level at screening is non-castrate (>=  ng/dl); men previously treated with intermittent hormonal therapy are also eligible if level of testosterone at screening is non-castrate (>=  ng/dl)
PSA at least  ng/mL
Serum prostate specific antigen equal to or less than  ng/mL
Have a PSA less than  ng/mL,
Have a PSA density less than . ng/ml/cc,
Have a PSA velocity less than  ng/ml yearly in the year prior to diagnosis,
PSA must be <  ng/mL at study entry
Screening PSA >= . ng/mL for men who had a prostatectomy; prior treatment with neoadjuvant, adjuvant or salvage radiation therapy is allowed, again, with screening PSA >= . ng/mL required for eligibility
Screening PSA >= . ng/mL above their postradiation nadir for men who were treated with primary radiation therapy (external beam and/or brachytherapy); men who had primary radiation therapy followed by salvage prostatectomy are eligible if screening PSA >= . ng/mL
Stable and undetectable PSA level (PSA < . ng/mL using an assay that has a functional sensitivity of . ng/mL) for at least two years after radical prostatectomy
Prostate-specific antigen (PSA) level of . -  ng/dl
PSA >  ng/dl
PSA < . ng/dL
Detectable PSA, defined as PSA >= . ng/ml
Persistent PSA after prostatectomy for PSA >= . ng/mL
Ferritin >=  ng/mL
Prostate-specific antigen (PSA) >= . ng/ml
Diagnostic prostate specific antigen (PSA) =<  ng/ml
PSA of - ng/mL
(OH)D level less than  ng/ml prior to stage  initiation
Post-operative prostate-specific antigen (PSA) < . ng/mL by  days after prostatectomy
Screening serum PSA <  ng/mL; for men treated with -alpha-reductase inhibitors (e.g., finasteride, dutasteride), PSA needs to be <  ng/mL
PSA within the past  months is between  and  ng/ml if patient received local radiation OR between . and  ng/ml if patient received prior radical prostatectomy
Patient with PSA less than or equal to  ng/mL
COHORT I: Biochemical recurrence defined as any of the following:\r\n* PSA >= . ng/mL in at least two consecutive tests within  months of date of consent for patients treated with surgery, radiation therapy, brachytherapy, or cryotherapy\r\n* PSA >= . ng/ml above the most recent therapy nadir for patients who have received additional treatment in the recurrent setting
Prostate-specific antigen (PSA) >= . ng/ml at time of enrollment.
PSA values ranging from . ng/mL to  ng/mL
Rising PSA after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy)\r\n* Post radical prostatectomy (RP)  American Urological Association (AUA) recommendation\r\n** PSA greater than . ng/mL measured more than  weeks after RP and,\r\n** Confirmatory persistent PSA greater than . ng/mL\r\n* Post-radiation therapy American Society for Therapeutic Radiology and Oncology (ASTRO) (ASTRO)-Phoenix consensus definition\r\n** Nadir + greater than or equal to  ng/mL rise in PSA
Rising PSA after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy)\r\n* If post-radical prostatectomy, PSA > . ng/mL measured >  weeks post-operatively and confirmatory persistent PSA greater than . ng/mL (American Urological Association [AUA] recommendation for biochemical recurrence)\r\n* If post-radiation therapy, PSA that is equal to, or greater than, a  mg/mL rise above PSA nadir (American Society for Radiation Oncology [ASTRO] recommendation for biochemical recurrence)
SUB-STUDY II: Biochemical recurrence with PSA > . ng/mL on two successive tests
Rising PSA after definitive therapy with prostatectomy or radiation therapy.\r\n* Post radical prostatectomy (RP)\r\n** PSA equals to or greater than . ng/mL measured more than  weeks after RP\r\n* Post-radiation therapy  American Society for Therapeutic Radiation and Oncology (ASTRO)-Phoenix consensus definition\r\n** Nadir + greater than or equal to  ng/mL rise in PSA
PSA < . ng/ml at enrollment
PSA >=  ng/mL
Rising PSA after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy\r\n* Post radical prostatectomy (RP)  American Urological Association (AUA) recommendation\r\n** PSA greater than . ng/mL measured  weeks after RP\r\n** Confirmatory persistent PSA greater than . ng/mL\r\n* Post-radiation therapy  American Society for Therapeutic Radiology and Oncology (ASTRO)-Phoenix consensus definition \r\n** Nadir plus (+) greater than or equal to  ng/mL rise in PSA
PSA <  ng/mL
Serum prostate specific antigen (PSA) =<  ng/ml within  months of study enrollment
Having elevated prostate specific antigen (PSA) (> . ng/ml) and no palpable nodule on digital rectal exam (DRE)
Rising PSA after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy)\r\n* Post radical prostatectomy (RP)  American Urology Association (AUA) recommendation\r\n** PSA greater than . ng/mL measured  weeks after RP\r\n** Confirmatory persistent PSA greater than . ng/mL\r\n* Post-radiation therapy American Society for Radiation Oncology (ASTRO)-Phoenix consensus definition\r\n** Nadir + greater than or equal to  ng/mL rise in PSA
Prostate-specific antigen (PSA) within  months prior to study consent or within  days after study consent <  ng/mL
Serum PSA level >= . ng/mL at least  days prior to study enrollment
Two PSA values >= . ng/mL at least  weeks after prostatectomy
Patient will have suspicion of recurrent prostate carcinoma as defined by: the American Society for Therapeutic Radiology and Oncology (ASTRO)-Radiation Therapy Oncology Group (RTOG) Phoenix criteria of elevated prostate-specific antigen (PSA) greater than nadir plus  ng/ml with absolute PSA >= . ng/ml with any doubling time (DT) or with PSA .-. ng/ml with DT =< months
Rising PSA after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy)\r\n* Post radical prostatectomy (RP)  American Urological Association (AUA) recommendation\r\n** PSA greater than . ng/mL measured more than  weeks after RP and\r\n** Confirmatory persistent PSA greater than . ng/mL\r\n* Post-radiation therapy American Society for Radiation Oncology (ASTRO)-Phoenix consensus definition\r\n* Nadir + greater than or equal to  ng/mL rise in PSA
Patient has suspected recurrence based on biochemical data (prostate-specific antigen [PSA] >  ng/mL)
PSA <  ng/ml (this will be the PSA level prompting the initial prostate biopsy)
Abnormal prostate-specific antigen (PSA) blood test\r\n* > . ng/mL for men <  years (yrs) of age\r\n* > . ng/mL for men <  yrs of age\r\n* > . ng/mL for men <  yrs of age
Prostate specific antigen (PSA) <  ng/mL
ARM II ONLY: For patients status post prostatectomy, a PSA >= . ng/ml
Serum PSA ? ng/ml within the previous  months
Post prostatectomy: Detectable or rising PSA level that is >. ng/mL with a second confirmatory level of >. ng/mL
Post non-prostatectomy: PSA rise ? ng/mL over nadir
Patient has suspected recurrence based on biochemical data (prostate specific antigen [PSA] >  ng/mL)
Increased PSA level > ng/mL
Abnormal serum PSA (total > . ng/ml or other clinically important biomarker parameters, including PSA velocity and density) associated with or without normal digital rectal examination
Prostate-specific antigen (PSA) <  ng/mL
